Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22775583 | 0.83 | CYP1A2 (0.57) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL19695691 | 0.83 | CYP1A2 (0.57) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL29604659 | 0.83 | CYP1A2 (0.57) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL5286013 | 0.81 | CYP1A2 (0.55) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL5560850 | 0.81 | CYP1A2 (0.55) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL10680648 | 0.81 | CYP1A2 (0.55) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL7271754 | 0.81 | CYP1A2 (0.55) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL6371067 | 0.81 | CYP1A2 (0.55) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL7270296 | 0.81 | CYP1A2 (0.55) | CYP1A2SLC7A5PTGS1PKMALPI | |
| SCHEMBL5283327 | 0.81 | CYP1A2 (0.55) | CYP1A2SLC7A5PTGS1PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3427737-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NeuroVive Pharmaceutical AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| EP-2654753-B1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-10-31 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-9139613-B2 | Macrocyclic compounds and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-22 | — | — | US | disclosed |
| EP-2691413-B1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-12-24 | — | — | EP | disclosed |
| EP-2770977-A1 | NOVEL DOSAGE FORM | Neurovive Pharmaceutical AB (SE) | 2014-09-03 | — | — | EP | disclosed |
| US-20140234414-A1 | Novel Dosage Form | Abliva Ab (SE) | 2014-08-21 | — | — | US | disclosed |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | Neurovive Pharmaceuticals AB (SE) | 2014-03-20 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| EP-2691413-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | Neurovive Pharmaceutical AB (SE) | 2014-02-05 | — | — | EP | disclosed |
| EP-2654753-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | Neurovive Pharmaceutical AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012131377-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012085553-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234414-A1 | Novel Dosage Form | SI, RAB10, SAMM50 | CYP1A2 567/4885SLC7A5 1786/4885PTGS1 526/4885 |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | MAVS, HDGF, TTPA | CYP1A2 589/4885SLC7A5 4617/4885PTGS1 459/4885 |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | HAVCR2, RPL35, CD4 | CYP1A2 184/4885SLC7A5 1425/4885PTGS1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.